Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;47(Supp1):S79-S84.
doi: 10.5152/tud.2021.21006.

Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

Affiliations

Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

Charles Van Praet et al. Turk J Urol. 2021 Feb.

Abstract

Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: C.V.P. participated in ad boards from Astellas. A.B. participated in ad boards from Ipsen, Novartis and BMS. K.D. is a consultant for Intuitive Surgical.

Figures

Figure 1
Figure 1
Proposed flowchart for treatment of clear-cell metastatic renal cell carcinoma based on International mRCC Database Consortium risk factors

Similar articles

Cited by

References

    1. Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, et al. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol. 2014;48:231–8. doi: 10.3109/21681805.2013.864698. - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Cancer J Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019;5:164–70. doi: 10.1001/jamaoncol.2018.5543. - DOI - PMC - PubMed
    1. Mejean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018;379:417–27. doi: 10.1056/NEJMoa1803675. - DOI - PubMed
    1. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol. 1978;120:148–52. doi: 10.1016/S0022-5347(17)57082-2. - DOI - PubMed

LinkOut - more resources